Holen Sie sich die Stockscreener-App
2.07
0.49%
0.010
Handel nachbörslich:
2.09
0.02
+0.97%
Schlusskurs vom Vortag:
$2.06
Offen:
$2.02
24-Stunden-Volumen:
2.67M
Relative Volume:
0.69
Marktkapitalisierung:
$478.05M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-7.3929
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
+13.11%
1M Leistung:
-2.82%
6M Leistung:
+51.09%
1J Leistung:
+52.21%
1-Tages-Spanne:
$2.01
$2.16
1-Wochen-Bereich:
$1.82
$2.16
52-Wochen-Spanne:
$0.80
$2.89
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.07 | 478.05M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.25B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Lobbying Update: $45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Barchart.com
US High Growth Tech Stocks to Watch in 2023 - Yahoo Finance
Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener
Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN
Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire
EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com Australia
EMA panel endorses Akebia’s kidney disease treatment - Investing.com India
Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment - MarketScreener
Akebia Therapeutics' (AKBA) Xoanacyl Receives EMA Panel Endorsem - GuruFocus
Akebia says kidney drug endorsed in EU (AKBA:NASDAQ) - Seeking Alpha
Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months - MarketScreener
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
Akebia Therapeutics Expands Team with Strategic Stock Options for 8 Key Hires - Stock Titan
Jefferies Initiates Coverage of Akebia Therapeutics (AKBA) with Buy Recommendation - Nasdaq
Jefferies sets Akebia Therapeutics stock at Buy, $6 price target By Investing.com - Investing.com Canada
Jefferies Initiates Akebia Therapeutics at Buy With $6 Price Target - MarketScreener
Akebia initiated with a Buy at Jefferies - TipRanks
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - MSN
Piper Sandler maintains Akebia stock with $6 price target By Investing.com - Investing.com Canada
Akebia Therapeutics to Present Research at National Kidney Foundation Spring Clinical Meetings 2025 - Nasdaq
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 - GlobeNewswire
Breakthrough Kidney Disease Treatment Data: Akebia's Vadadustat Shows Promising Results - Stock Titan
Akebia Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - MSN
Akebia Stock Drops 28% On Pricing Of $50M Common Stock Offering - Barchart
Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA) - Seeking Alpha
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? - MSN
Akebia Therapeutics Announces $50 Mln Public Offering Of Common Stock - Nasdaq
Akebia Therapeutics Announces Public Offering Pricing - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33% - Simply Wall St
Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale - TradingView
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Akebia Therapeutics Prices $50 Million Public Offering -March 20, 2025 at 04:19 am EDT - Marketscreener.com
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock -March 19, 2025 at 10:18 pm EDT - Marketscreener.com
Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - StockTitan
‘Buckle Up for Another Surge,’ Says Cowen About Nvidia Stock - The Globe and Mail
Akebia Therapeutics launches public stock offering By Investing.com - Investing.com South Africa
2 No-Brainer Biotech Stocks to Buy Right Now - The Globe and Mail
SEC Form 424B5 filed by Akebia Therapeutics Inc. - Quantisnow
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):